The Wegovy Pill: Oral Semaglutide for Weight Loss in the UK

You've heard about the injection, and wondered whether there's a tablet instead

It's a question our prescribers hear regularly. The idea of a once-weekly pen puts some people off, and for those who have been waiting for an alternative, the Wegovy pill answers it. Approved by the MHRA on 11 June 2026, it made the UK the first country in Europe to licence an oral GLP-1 medicine specifically for weight management. That is not a small distinction. For years, injectable semaglutide was the only way to access this treatment pathway as a tablet.

The active ingredient is semaglutide, the same molecule found in the injectable form. It is co-formulated with a compound called SNAC, which helps the semaglutide cross the stomach lining and reach the bloodstream. Without SNAC, oral semaglutide would be broken down before it could act. The mechanism from that point is identical to the injection: semaglutide activates GLP-1 receptors, slowing gastric emptying and reducing appetite signals, so most people find they feel full earlier and stay satisfied for longer between meals.

What the tablet cannot do is replicate the injection's pharmacokinetics exactly. Absorption is more variable with the oral route, which is partly why the maintenance dose (25mg) is considerably higher than the injection's 2.4mg. The two formulations are not interchangeable by dose number, only by mechanism and, broadly, by outcome trajectory.

What taking the tablet actually involves, the morning routine that makes or breaks it

The administration requirement is specific, and it matters. The Wegovy tablet must be taken first thing in the morning, on a completely empty stomach, with no more than a small amount of plain water, around 120ml. After swallowing it whole, you then wait at least 30 minutes before eating, drinking anything else (including coffee or tea), or taking other oral medicines. That window allows the SNAC to facilitate absorption before food or drink dilutes the conditions in the stomach.

For many people, building this into a morning routine is straightforward: tablet on the bedside table, sip of water, phone on, kettle on thirty minutes later. A practical checking habit that takes under a minute: set a repeating morning alarm labelled 'tablet, then wait' so the 30-minute gap becomes automatic rather than something you mentally track each day. The full preparation guidance is worth reviewing before you start.

The tablet is stored at room temperature. There is no fridge required, no pen to keep cool, and no concern about the short window injectable pens have once removed from refrigeration. For people who travel frequently for work or face storage limitations at home, that practicality is genuinely useful. The MHRA's approval announcement confirmed the room-temperature storage as part of the licensed presentation.

Who the MHRA licence covers, and what the clinical trial found

The Wegovy tablet is licensed for adults with a BMI of 30 or above, or those with a BMI between 27 and 29.9 who have at least one weight-related condition, such as high blood pressure, raised cholesterol, or obstructive sleep apnoea. It is taken alongside a reduced-calorie diet and increased physical activity, not instead of them. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

The pivotal evidence comes from the OASIS 4 phase 3 trial, which followed 307 adults with obesity or overweight and at least one weight-related condition over 64 weeks, all without type 2 diabetes. Average weight loss across the whole group was around 13.6%, compared with approximately 2.4% on placebo. Among participants who adhered fully to treatment, the figure rose to around 17%. It is worth being clear about the difference: 17% is the fully-adherent subgroup figure, not the average for everyone who started the trial. The STEP 1 trial results for the weekly injection offer a useful comparison if you want to weigh up the two routes.

The most common side effects reported in the trial were gastrointestinal: nausea, diarrhoea, vomiting, and constipation affected around 74% of participants on the tablet versus 42% on placebo. These are generally mild to moderate and tend to settle as the body adjusts, particularly during the early dose-escalation stages. The slow titration schedule exists precisely to give the digestive system time to adapt. As with all semaglutide-based treatments, the Wegovy tablet carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring by the MHRA while post-marketing data accumulates.

The NHS position, and what a private consultation involves

The Wegovy tablet was approved too recently for a NICE technology appraisal to have been completed. Until NICE assesses it and makes a recommendation, the tablet is not available through the NHS; access is currently by private prescription only. That may change, but there is no confirmed timeline. The weekly Wegovy injection is available through specialist NHS weight management services under NICE TA875, though waiting lists are commonly long.

For the cost context of private semaglutide treatment in the UK, the Wegovy pricing page sets out what private providers typically charge and what those prices do and do not include. Because the tablet is a prescription-only medicine, any legitimate route to it begins with a clinical consultation. At nume, a GPhC-registered Independent Prescriber reads every consultation personally, the same day. There are no subscriptions and no automatic renewals; each repeat order goes through a fresh clinical review. If you would like to explore whether the Wegovy tablet is clinically suitable for you, check your eligibility and our prescribers will take it from there.